Forest To Review Role In Desmoteplase Program Following DIAS-2 Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryDevelopment of Forest/Paion's clot dissolving protein desmoteplase for the treatment of acute ischemic stroke could be in question after a Phase III study failed to show an efficacy benefit in patients treated with the drug versus placebo
You may also be interested in...
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.